ClinicalTrials.gg
RecruitingNCT02275195Updated Jan 12, 2024

Immune Cell Dysfunction in Severe Alcoholic Hepatitis

An observational study in Hepatitis, sponsored by Mid and South Essex NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-01-12.

Sponsored by Mid and South Essex NHS Foundation Trust · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
50
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Hepatitis with a site in United Kingdom — 6 open to participants now, 11 under way, 2 of them phase 3. Hepatitis · United Kingdom.

Started
2013
with 3 others
Observational
4 of 31
3 open now
Primary completion
2024-12
later than 1 of 10 live
Registered
12th of 31
by date

Among the 31 studies in Hepatitis with a site in United Kingdom, this one is one of 4 that started in 2013, is one of 4 observational ones, reaches primary completion later than 1 of the 10 other live ones, and was the 12th registered.

Hepatitis

344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

Browse Hepatitis studies →

Open to participants now

6 of the 31 studies in Hepatitis with a site in United Kingdom are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 36 Hepatitis studies recruiting now, 23 (64%) set no upper age limit and 11 (31%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hepatitis with a site in United Kingdom, or all of them as a file.
02

Study summary

Through bio-sampling this study investigates the relationship between the frequency and function of the cells of a patients immune system and how these change and impact on the outcome of alcoholic hepatitis. the investigators will examine the role of different cells of the immune system and how they may determine the outcome of this condition. The investigators will also look at how established treatment strategies impact on the frequency and function of these cell subsets.

Read the detailed description

Through bio-sampling this study investigates the relationship between the frequency and function of the cells of a patients immune system and how these change and impact on the outcome of alcoholic hepatitis. The investigators will examine the role of different cells of the immune system and how they may determine the outcome of this condition. The investigators will also look at how established treatment strategies impact on the frequency and function of these cell subsets.

Alcohol is the most common cause of liver disease in the developed world and results in the death of 2.5 million people annually. It is a causal factor in more than 60 major types of diseases and injuries and approximately 4.5% of the global burden of disease and injury is attributable to alcohol. Acute alcoholic hepatitis (AAH) is perhaps the most florid form of ALD and the leading cause of mortality in these patients is the development of sepsis which occurs in up to 40% of these patients and has a mortality rate of 50%.

By gaining a better understanding of the relationship between elements of the immune system and the progression to severe alcoholic hepatitis, it will allow the formulation of more effective treatment strategies for this condition.

Patients who agree to participate in this study will have an extra 40mls of blood drawn for scientific studies at the same time as routine blood samples are taken as part of their ongoing care.

03

Conditions studied

  • Hepatitis

Browse trials for

Keywords

  • hepatitis
  • alcohol
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients attending / being treated at the Basildon Hospital for acute severe alcoholic hepatitis will be identified as potential participants in these studies

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years
  2. Patients presented with severe alcoholic hepatitis with a Maddrey score (discriminant function) of >32 (The Maddrey score uses various blood results on a patient to define the severity of alcoholic hepatitis e.g. etc).
  3. Ongoing abuse of alcohol (drinking in excess of 28 units/wk)

Exclusion criteria

Exclusion Criteria:

  1. Co-infection with / / virus infection.
  2. Patients with liver disease.
  3. Patients with metabolic liver disease.
  4. Patients with significant psychiatric and/or neurological co-morbidity.
  5. Hepatocellular carcinoma or other neoplastic disease
  6. Pregnancy or breast feeding of infants.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. To determine and changes to immune cell responses for outpatients with Alcoholic Hepatitis

    Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis

    Time frame: Participants will be followed-up during thier hospital stay, which averages 4 weeks

Secondary outcomes

  1. Change from baseline to end of study in flow cytometry for patients with Alcoholic Hepatitis

    Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis

    Time frame: on average 4 weeks

  2. Change from baseline to end of study in real time PCR for patients with Alcoholic Hepatitis

    Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis

    Time frame: On average 4 weks

  3. Change from baseline to end of study in cell cultures for patients with Alcoholic Hepatitis

    Characterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis

    Time frame: on average 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Dec 2024 and a completion of Dec 2024. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2014
First posted
Oct 27, 2014
Start
Nov 2013
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2024
Last update
Jan 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02275195
Lead sponsor
Mid and South Essex NHS Foundation Trust
Responsible party
Sponsor
First posted
Oct 27, 2014
Start date
Nov 2013
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
Jan 12, 2024

Study contacts

Carol L Alves, BSc, MRes
Contact
Carol.Alves@btuh.nhs.uk
01268 529400 ext. 3599
Gavin Wright, MBBS MRCP
principal investigator · Basildon and Thurrock University Hospitals NHS FT

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion